Dermatology Products · LP-091
Diclofenac sodium Gel
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-091Dermatology Products
- Generic identity
- Diclofenac sodiumGel
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-091
- Generic ingredient
- Diclofenac sodium
- Dosage form
- Gel
- Proposed strength
- 1%; 2%
- Proposed pack
- Tube 20 g / 30 g
- Portfolio category
- Dermatology Products
About Diclofenac sodium
Diclofenac is a non-steroidal anti-inflammatory drug that can be formulated as a topical gel for selected localized painful conditions. A gel is different from an oral tablet, and concentration alone does not establish equivalence between topical products. Skin absorption is lower than systemic administration in many settings, but not zero. This educational profile does not establish Luang Pharma approved indications, application instructions or systemic-exposure data.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
A professional should identify the cause of pain and confirm that the affected area and condition fit the locally authorized topical use. Persistent joint swelling, trauma with functional loss, fever or unexplained pain may require examination. A gel should not be assumed suitable for every musculoskeletal complaint. Other NSAIDs and anticoagulants need review. The exact formulation determines the appropriate application site, permitted duration and any restrictions concerning dressings or heat.
Important safety considerations
Local irritation or dermatitis may occur, while systemic NSAID effects and serious allergy remain possible. A history of aspirin- or NSAID-triggered asthma requires particular review. Avoid the eyes, mucous membranes and damaged skin unless the exact approved instructions permit otherwise. Pregnancy, especially later pregnancy, requires professional assessment. Concurrent oral NSAIDs can increase risk. Severe rash, breathing difficulty, black stools or other concerning symptoms should prompt medical review rather than continued application.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
The catalogue identifies a topical gel. The salt-equivalence basis, vehicle and concentration must be verified because different diclofenac products can express strengths differently. Gel composition affects application and precautions; a percentage alone does not establish equivalence or permission to use heat or occlusive dressings.
Follow the supplied topical instructions and keep the container properly closed and labeled. Avoid accidental eye contact or ingestion. Storage, flammability, permitted application area and any after-opening limit depend on the actual formulation and must not be inferred from another gel.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
A clinician or pharmacist should confirm the skin diagnosis, application site, extent and suitability of the exact formulation. Unexplained, spreading or recurrent lesions need assessment. Product-specific instructions determine age restrictions, handling and permitted use.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Diclofenac sodium
- Dosage form / presentation
- Gel
- Catalogue strength
- 1%; 2%
- Catalogue pack
- Tube 20 g / 30 g
- Portfolio category
- Dermatology Products
Layer 02
Unresolved product-specific fields
- Source labels diclofenac sodium 1% and 2%; verify salt-versus-active equivalence and exact topical vehicle. Do not map automatically to differently expressed comparator products.
- Exact vehicle/excipient system, intended application site and formulation-specific instructions require controlled product documentation.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- NHS: Diclofenac — clinical backgroundpublic-health medicine reference
- NHS: Diclofenac — side effectspublic-health medicine reference
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-091, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-091.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.